Table 2

Baseline characteristics of patients with SLE

Characteristics of patients with SLE (n=72)
N (%) or mean±SD
Disease duration*12.0±1.9
History of
 Malar rash27 (37.5%)
 Discoid9 (12.5%)
 Mouth ulcers41 (56.9%)
 Alopecia39 (54.2%)
 Arthritis57 (79.2%)
 Serositis36 (50.0%)
 Proteinuria27 (37.5%)
 Seizure2 (2.8%)
 Haemolytic anaemia6 (8.3%)
 Leucopaenia37 (51.4%)
 Thrombocytopaenia15 (20.8%)
 ANA70 (97.2%)
 Anti-dsDNA38 (52.8%)
 Lupus anticoagulant24 (33.3%)
 Anticardiolipin51 (71.8%)
 Anti-B2 glycoprotein24 (33.3%)
 Low C346 (63.9%)
 Low C435 (48.6%)
 Direct Coomb’s test12 (16.7%)
At baseline CTA
 SELENA-SLEDAI1.7±2.1
 PGA0.6±0.7
 Hydroxychloroquine use63 (87.5%)
 Immunosuppressant use26 (36.1%)
 Prednisone use15 (20.8%)
 Statin use20 (27.8%)
 Antihypertensive use44 (61.1%)
  • *Disease duration at the time of baseline CTA.

  • CTA, CT angiography; PGA, physician global assessment; SELENA-SLEDAI, Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus.